| |DECEMBER 20249LABORIE SECURES NEW AMA CPT CODE FOR ADVANCED PROSTATE PROCEDUREDR REDDY'S SECURES CDSCO NOD, BECOMES FIRST TO LAUNCH ELOBIXIBAT IN INDIALaborie Medical Technologies Corp (Laborie), a top company in diagnostic and therapeutic medical technology, disclosed that the American Medical Association (AMA) has introduced the new Category 1 Current Procedural Terminology (CPT) code 52XX2 for documenting cystourethroscopy, along with initial transurethral anterior prostate commissurotomy.The fresh code applies to services carried out by doctors using Laborie's Optilume BPH Catheter System, a minimally invasive surgical therapy (MIST) that involves mechanical dilation using a unique double-lobe balloon along with simultaneous localized administration of paclitaxel for the treatment of lower urinary tract symptoms (LUTS) caused by BPH.Optilume BPH sets a new standard in treating BPH-induced LUTS with the highest Qmax recorded in BPH MIST clinical trials to date (19mL/sec at 2 years), offering immediate and long-lasting symptom relief and minimal recovery time for men. The technology was created to address the dissatisfaction patients and doctors have with existing treatment choices."This is a significant milestone for Optilume BPH, and we welcome the AMA Editorial Panel's decision," said Michael Frazzette, Laborie's President and CEO. "The new code will broaden patient access by establishing a reimbursement pathway for this important treatment and will help enable adoption at various sites of care."Starting from January 1, 2026, healthcare professionals have the option to record the updated CPT code for Optilume BPH. Developed and upheld by the AMA, CPT codes are commonly utilized to depict medical services and procedures for easier reimbursement by both public and private health insurance companies in the United States. PODr Reddy's is the first leading pharmaceutical company to obtain approval from the Central Drugs Standard Control Organisation (CDSCO) to introduce Elobixibat in India. Elobixibat works by preventing bile acids from being reabsorbed in the ileum, which results in higher levels of bile acids in the colon. This leads to a boost in bowel movements by enhancing colonic motility and fluid secretion, regardless of how quickly food moves through the digestive system.Dr Reddy's Laboratories announced the introduction of a groundbreaking medication for treating chronic constipation. The drug firm based in Hyderabad said in a statement that the company will launch the drug in India with the brand name BixiBat."The launch of this first-in-class drug is the latest in our continued efforts to bring novel molecules to patients in India," Dr Reddy's CEO Branded Markets (India and Emerging Markets) MV Ramana said.He mentioned that the clinical trials for BixiBat have shown much improved and hopeful results, making it a revolutionary medication for treating chronic constipation and improving the current treatment standards in India.Dr. Reddy's Laboratories, headquartered in Hyderabad, is a multinational pharmaceutical firm from India. Kallam Anji Reddy, who had prior experience at Indian Drugs and Pharmaceuticals Limited, established the company. Dr. Reddy produces and sells a diverse array of medications in both India and abroad. PO
< Page 8 | Page 10 >